Mirtazapine Shows Promise for Methamphetamine Use Disorder in Phase 3 Trial
核心洞察
A phase 3 randomized clinical trial of 339 patients found that mirtazapine 30 mg daily reduced methamphetamine use by an average of 7 days compared to 4.8 days with placebo over 12 weeks.
The study represents the first large-scale trial of a readily available antidepressant for methamphetamine use disorder (搜索), addressing a critical unmet need with no approved medications worldwide.
While the treatment effect was modest (2.2 fewer use days), mirtazapine offers a safe, affordable option that could be prescribed off-label by physicians familiar with its use in depression (搜索).
A phase 3 randomized clinical trial has demonstrated that mirtazapine, a commonly prescribed antidepressant, can reduce methamphetamine use in patients with moderate to severe methamphetamine use disorder (搜索). The double-blind, placebo-controlled study, conducted across six outpatient clinics in Australia, represents the largest trial to date examining a potential medication treatment for methamphetamine dependence.
Trial Design and Patient Population
The Tina Trial enrolled 339 patients with methamphetamine use disorder (搜索) who received either mirtazapine 30 mg daily or placebo for 12 weeks. At baseline, participants reported methamphetamine use on a median of 24 of the past 28 days, with an average of 22 days of use. The study population was notably diverse, including both men and women, and patients with and without depression (搜索).
"Mirtazapine can be used in routine clinical practice to facilitate a reduction in methamphetamine use among people with a moderate to severe methamphetamine use disorder (搜索)," wrote lead study author Rebecca McKetin, PhD, of the University of New South Wales, Sydney, Australia, and colleagues.
Primary Efficacy Results
By week 12, patients receiving mirtazapine showed a reduction in methamphetamine use of 7 days compared to 4.8 days in the placebo group. This translated to an 8% lower risk of methamphetamine use on any given day with mirtazapine treatment. The mean reduction across all follow-up time points was 1.8 fewer days of use, representing a modest but statistically significant benefit.
The comparative advantage of mirtazapine was 2.2 fewer days of use out of 28 days compared to placebo. Importantly, this benefit was observed regardless of whether patients had depression (搜索) at baseline, suggesting mirtazapine's effect on methamphetamine use may be independent of its antidepressant properties.
Safety and Tolerability Profile
Adverse events were more common in the mirtazapine group, with drowsiness reported in 47% of patients compared to 33% receiving placebo. Weight gain occurred in 10% of mirtazapine patients versus 3% on placebo. Discontinuation due to adverse events occurred in 23% of patients receiving mirtazapine compared to 15% receiving placebo.
Serious adverse events occurred in 5% of patients overall and were not considered treatment-related. The researchers noted no unexpected safety issues when using mirtazapine for methamphetamine use disorder (搜索).
Addressing an Unmet Medical Need
An estimated 7.4 million people worldwide are dependent on methamphetamine, facing multiple health risks including paranoia, suicidal ideation, cardiovascular problems, strokes, and increased risk of early death. Australia has one of the highest rates of methamphetamine dependence per capita globally.
Currently, no medications are approved anywhere in the world specifically for treating methamphetamine dependence. Available treatment options are limited to counseling, detoxification, and residential rehabilitation programs, which often have high dropout rates and limited accessibility.
Clinical Implications and Future Directions
The study builds on earlier smaller trials conducted in San Francisco that showed similar benefits of mirtazapine in reducing methamphetamine use. However, those studies involved smaller, more homogeneous patient populations monitored in research clinic settings.
The researchers believe mirtazapine has a direct effect on methamphetamine dependence, distinct from its antidepressant properties, potentially acting on brain reward systems that chronic methamphetamine use can disrupt.
Mirtazapine offers several practical advantages as a potential treatment: it is inexpensive, widely available as a generic medication, and familiar to many physicians who prescribe it for depression (搜索). As a take-home medication, it eliminates the need for daily clinic visits or intensive medical monitoring.
Study Limitations
The researchers acknowledged that treatment effects may have been attenuated by heterogeneous patient characteristics, moderate medication adherence, and discontinuation rates typical of routine clinical practice. The outpatient design, while improving generalizability, may have diluted treatment effects compared to more controlled research settings.
No statistically significant differences were observed between groups in secondary outcomes including depression (搜索), insomnia (搜索), HIV risk behavior, quality of life, or methamphetamine-negative oral fluid samples. Among patients with baseline depression, mirtazapine was associated with greater reductions in insomnia scores at multiple time points.